![Jonathan Hanley](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jonathan Hanley worked as a Director of Functional Proteomics at GenOdyssee SA, Manager of Research & Development Alliance at Génomic Vision SA, Head of Biotechnology at National Physical Laboratory Ltd., and Analyst at Société Générale Asset Mgmt Alternative Invt (Private Equity).
He holds a Doctorate from University College London, an MBA from Ecole Nationale des Ponts et Chaussées, and an undergraduate degree from the University of Portsmouth.
| Unternehmen | Position | Ende |
|---|---|---|
Société Générale Asset Mgmt Alternative Invt (Private Equity)
 Société Générale Asset Mgmt Alternative Invt (Private Equity) Investment ManagersFinance SGAM AI/PE utilizes a top down investment approach drawing on the group's team of economists and analysts in addition to external research sources. They align the interest of their teams and the management of portfolio firms with those of their investors. They deploy their technical, sector, financial and managerial expertise in the private equity transactions. They are active private equity investment managers through board membership of their portfolio firms. SGAM AI/PE's venture capital investments are made up of new technologies, biotech and cardio-vascular focused investments. In information technology and engineering sciences, they generally seek early-stage investments initially between €750 thousand and €2.5 billion. Their strategy is to lead or co-lead investment rounds. They target firms in France and Europe in semi-conductors, networks and communications, digital media, software, environment, clean energy and other related industries such as aeronautics, automotive, etc. They look for experienced management teams, market leaders within a large market, rapidly scalable business models, high-level entry barriers, and sustainable competitive advantage with an exit strategy in five years. SGAM AI/PE's biotechnology investments are allocated in varying stages with a third in seed finance, a third in first round and the remainder in second or third round or later financing. The biotech team manages several different investment vehicles. Their investment portfolio is spread across Europe, in particular France, and the US. The investment size typically ranges from €1 million to €10 million. Within the sector, they focus on a wide variety of technologies such as companion diagnostics, regenerative medicine, bio-analysis tools, pharmaceutical manufacturing process technology, predictive in vivo modeling, genomics and proteomics and in silico chemistry tools. SGAM AI/PE's French SME team provides equity finance for unlisted small- and mid-sized firms in France with enterprise values between €5 million to €6 million for expansion capital and minority buyouts. They manage two different funds invested by both private and institutional investors. SGAM AI/PE's fund of funds group manages investments in venture capital, LBOs, turnaround, mezzanine and distressed debt funds in the US, UK, Europe and Asia. | Private-Equity-Analyst | 16.02.2010 |
National Physical Laboratory Ltd.
 National Physical Laboratory Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a research institute for developing and applying the measurement standards, science and technology | Corporate Officer/Principal | - |
GenOdyssee SA
 GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services Provides genetics-based drug discovery services | Corporate Officer/Principal | - |
| GENOMIC VISION | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 7 |
|---|---|
GenOdyssee SA
GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services Provides genetics-based drug discovery services | Commercial Services |
Ecole Nationale des Ponts et Chaussées
 Ecole Nationale des Ponts et Chaussées Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Portsmouth
 University of Portsmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Société Générale Asset Mgmt Alternative Invt (Private Equity)
Société Générale Asset Mgmt Alternative Invt (Private Equity) Investment ManagersFinance SGAM AI/PE utilizes a top down investment approach drawing on the group's team of economists and analysts in addition to external research sources. They align the interest of their teams and the management of portfolio firms with those of their investors. They deploy their technical, sector, financial and managerial expertise in the private equity transactions. They are active private equity investment managers through board membership of their portfolio firms. SGAM AI/PE's venture capital investments are made up of new technologies, biotech and cardio-vascular focused investments. In information technology and engineering sciences, they generally seek early-stage investments initially between €750 thousand and €2.5 billion. Their strategy is to lead or co-lead investment rounds. They target firms in France and Europe in semi-conductors, networks and communications, digital media, software, environment, clean energy and other related industries such as aeronautics, automotive, etc. They look for experienced management teams, market leaders within a large market, rapidly scalable business models, high-level entry barriers, and sustainable competitive advantage with an exit strategy in five years. SGAM AI/PE's biotechnology investments are allocated in varying stages with a third in seed finance, a third in first round and the remainder in second or third round or later financing. The biotech team manages several different investment vehicles. Their investment portfolio is spread across Europe, in particular France, and the US. The investment size typically ranges from €1 million to €10 million. Within the sector, they focus on a wide variety of technologies such as companion diagnostics, regenerative medicine, bio-analysis tools, pharmaceutical manufacturing process technology, predictive in vivo modeling, genomics and proteomics and in silico chemistry tools. SGAM AI/PE's French SME team provides equity finance for unlisted small- and mid-sized firms in France with enterprise values between €5 million to €6 million for expansion capital and minority buyouts. They manage two different funds invested by both private and institutional investors. SGAM AI/PE's fund of funds group manages investments in venture capital, LBOs, turnaround, mezzanine and distressed debt funds in the US, UK, Europe and Asia. | Finance |
Génomic Vision SA
 Génomic Vision SA Medical SpecialtiesHealth Technology Develops diagnostic tools using deoxyribonucleic acid analysis | Health Technology |
National Physical Laboratory Ltd.
National Physical Laboratory Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a research institute for developing and applying the measurement standards, science and technology | Commercial Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
